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Cancer response to immunotherapy depends on the infiltration of CD8+ T cells and the
presence of tumor-associated macrophages within tumors. Still, little is known about the
determinants of these factors. We show that LIF assumes a crucial role in the regulation of
CD8+ T cell tumor infiltration, while promoting the presence of protumoral tumor-associated
macrophages. We observe that the blockade of LIF in tumors expressing high levels of LIF
decreases CD206, CD163 and CCL2 and induces CXCL9 expression in tumor-associated
macrophages. The blockade of LIF releases the epigenetic silencing of CXCL9 triggering CD8
+ T cell tumor infiltration. The combination of LIF neutralizing antibodies with the inhibition of
the PD1 immune checkpoint promotes tumor regression, immunological memory and an
increase in overall survival.
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LIF is a pleiotropic cytokine with a critical dual function inembryonic development1,2. LIF regulates embryonic stemcell (ESC) self-renewal preventing early differentiation3 and
is required for blastocyst implantation in the uterus4. Specifically,
LIF generates a local immunosuppressive microenvironment in
order to protect the embryo from the mother’s immune system4–7.
Ablation of LIF in mice prevents embryo implantation, and
women with loss-of-function LIF mutations show infertility with
impairment of in vitro fertilization4–7. Thus, LIF is a master
regulator of embryo implantation through the regulation of the
immune tolerance in pregnancy.
LIF can act as an oncogenic factor through the induction of the
self-renewal of cancer-initiating cells8, the regulation of cancer-
associated fibroblasts9, as well as promoting radioresistance10 and
chemoresistance11. Importantly, the expression of LIF in cancer is
widely heterogeneous and some tumors express aberrantly high
levels of LIF while others do not express LIF12. Non-small cell
lung cancer, breast cancer, colorectal cancer, and nasopharyngeal
cancer patients with tumors expressing high levels of LIF exhibit a
shorter overall survival8–10 indicating that high LIF expression
might be involved in the oncogenic progression of these malig-
nancies. However, the molecular mechanisms underlying the role
of LIF in the immune response in cancer have not been
elucidated yet.
Here, we find that tumors expressing high levels of LIF tend to
be infiltrated with tumor-associated macrophages (TAMs). LIF
regulates the expression of CD163 and CD206, as well as several
chemokines including CXCL9 and CCL2 in TAMs. Specifically,
LIF triggers the epigenetic silencing of the CXCL9 locus by the
recruitment of EZH2 to the CXCL9 promoter. The blockade of
LIF in tumors expressing high levels of LIF releases the CXCL9
repression acting as a chemoattractant of cytotoxic CD8+ T cells.
LIF is then a crucial regulator of CD8+ T cell tumor infiltration.
Importantly, the combination of the blockade of LIF with
checkpoint inhibitors induces tumor regression, immune mem-
ory, and an increase in overall survival.
Results
LIF expression correlates with TAM tumor infiltration. To
study the effect of LIF on the cancer immune system, we first
determined whether LIF expression correlated with the presence
of tumor immune cell infiltrates in human cancer. We observed a
significant correlation between LIF and TAMs across several
tumor types of The Cancer Genome Atlas (TCGA) (Fig. 1a, b,
Supplementary Data 1). Glioblastoma (GBM), prostate adeno-
carcinoma, thyroid cancer and ovarian cancer were the 4 tumor
types exhibiting the highest correlations between LIF and TAMs,
while showing a high LIF expression across tumor samples
(Fig. 1a, b). A wide range of LIF expression was observed in GBM
tumors being it expressed by tumor cells and the immune cell
infiltrates (Supplementary Fig. 1).
The blockade of LIF induces an antitumor immune response.
We decided to use immunocompetent mouse models of GBM
and ovarian cancer (tumor types where LIF strongly correlates
with TAMs) to study the potential immune-modulating role of
LIF in cancer. We identified the GBM cell line, GL261N
(a derivative of the GL261 cell line), the GFAP-tv-a RCAS-
PDGFA, shp53, shNF1 (RCAS) transgenic model13 and the
ovarian cancer cell line, ID8, that generated tumors in the brain
(GL261N and RCAS) and peritoneum (ID8) of mice expressing
high levels of LIF (Supplementary Fig. 2a).
We repressed LIF function in GL261N, RCAS and ID8 models
using neutralizing antibodies, CRISPR/CAS9 or RNA interference
technologies and observed a decrease in tumor growth and a
modest increase in survival (Fig. 1c, e, h, i, l, n, q, Supplementary
Figs. 2b–f, 3e, f). The blockade of LIF in the GL261 tumor model,
a tumor that did not express LIF, did not inhibit tumor growth
(Supplementary Fig. 2a, g).
Neutralizing antibodies against LIF induced a marked decrease
in p-STAT3 levels showing that in these animal models (selected
based on high LIF expression) LIF was the main cytokine
inducing the JAK-STAT3 pathway (Fig. 1d, m). Moreover, while
we did not observe a significant decrease in Ki67 positive cells, we
detected an increase in cleaved caspase 3 (CC3) indicating that
the blockade of LIF induced tumor cell death (Fig. 1d, m).
In order to evaluate the role of the immune system in the
response to anti-LIF treatment, we performed experiments using
immunodeficient animals. Treatment of GL261N tumors in RAG
−/− or NOD SCID mice (both strains of mice lacking the adaptive
immune response) with anti-LIF did not show a significant
impact on tumor growth (Supplementary Fig. 2h). This indicated
that in our models the antitumor response to the blockade of LIF
was mainly mediated by the adaptive immune response.
We decided to further investigate the molecular mechanisms
involved in the immune response to anti-LIF treatment. We
observed a decrease in the number of protumoral TAMs (Fig. 1f,
j, o) and, importantly, a concomitant increase in tumor
infiltration of CD8+ T cells upon anti-LIF treatment (Fig. 1d, g,
k, m, p). Natural killer (NK) and regulatory T (Treg) cell numbers
increased and decreased upon treatment with anti-LIF, respec-
tively (Supplementary Fig. 2i–l). Infiltrating CD8+ T cells
expressed Granzyme A (GZMA) suggesting that they were
mediating the cytotoxic effect (Supplementary Fig. 3a). Moreover
a compartment of CD8+ T cells expressed PD1 (Supplementary
Fig. 3b, c). TAMs derived from recruited monocytes (CD11b+
Ly6G− Ly6C− CD49d+)14 were decreased in response to anti-LIF
or LIF shRNA (Supplementary Fig. 3d–f) and no major effect was
observed on the dendritic cell population (CD11b+, CD11c+,
MHCII+) (Supplementary Fig. 3g) nor on the levels of IL12 or
IL10 in the tissue (Supplementary Fig. 3h).
We then assessed whether the LIF-mediated regulation of the
tumor immune infiltrates was the cause or the consequence of the
antitumor response. To this end, we performed an acute
treatment experiment where we treated mice with established
tumors with anti-LIF for 4 days. The 4 day-treatment did not
affect tumor growth (Supplementary Fig. 3i) but was enough to
engage CD8+ T cell tumor infiltration (Supplementary Fig. 3j).
This showed that CD8+ T cell infiltration was not the result of the
anti-tumor response to the blockade of LIF.
LIF regulates the expression of protumoral cytokines in TAMs.
We isolated CD11b+ cells from the ID8 mouse model treated or
untreated with anti-LIF antibodies and performed a tran-
scriptomic analysis. Several genes related to an oncogenic phe-
notype were downregulated (i.e., CCL2, CCL3, CCL7, PF4, CTSK,
CD206, CD163) and, interestingly, CXCL9 was upregulated
(Fig. 2a, Supplementary Data 2). The aforementioned gene
responses were validated by qRT-PCR in the ID8 and GL261N
models (Fig. 2b).
CXCL9 and CCL2 stood out as chemokines described to be
critical for CD8+ T cell tumor infiltration, and the recruitment of
TAMs and Tregs15–17, respectively. We confirmed the CXCL9
and CCL2 regulation in TAMs (CD11b+ Ly6G− Ly6C−) by the
neutralization of LIF or LIF shRNA (Fig. 2c, Supplementary
Fig. 3k–m). Immunofluorescence (IF) and isolation of TAMs
showed that CXCL9, CCL2, CD206, and CD163 were mainly
expressed in TAMs (Fig. 2d, Supplementary Fig. 4, 5a) and
inhibition of LIF function regulated their expression (Fig. 2c, d,
Supplementary Figs. 3k–m, 4). CXCR3 (CXCL9 receptor), CCR2
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(CCL2 receptor) and LIFR were expressed in TAMs and CD8+
T cells (Supplementary Fig. 5b).
In order to address the relevance of the regulation of CXCL9
and CCL2 in the LIF oncogenic function, we used CXCL9 and
CCL2 knockout (CXCL9−/−, CCL2−/−) mouse models, and
blocking antibodies against CXCL9 and CCL2. Interestingly, the
anti-tumor response to the inhibition of LIF was blunted in the
CXCL9−/−mice but not in the CCL2−/−mice (Fig. 2e). Similarly,
the CXCL9 neutralizing antibody but not the CCL2 antibody
impaired the anticancer response to anti-LIF (Fig. 2e). These
results indicated that the main mediator of the anti-LIF response
was CXCL9. As expected, the blockade of CXCL9 prevented the
increase of CD8+ T cell tumor infiltration in response to anti-LIF
(Fig. 2f). We then investigated whether the TAM-specific
expression of CXCL9 was responsible for the regulation of the
tumor infiltration of CD8+ T cells. We generated GL261N
tumors in CXCL9−/− and CCL2−/− mice and hence the tumors
were infiltrated with CXCL9−/− or CCL2−/− TAMs. We then
transplanted the tumors into wild type mice and assessed CD8+ T
cell tumor infiltration in response to the blockade of LIF. We
observed that the TAM-specific deletion of CXCL9 reduced the
infiltration of CD8+ T cells in response to the blockade of LIF
(Supplementary Fig. 5c, d). In contrast, the TAM-specific deletion
of CCL2 did not impact on the CD8+ T cell tumor recruitment
(Supplementary Fig. 5c, d).
We went back to the analysis of TCGA datasets of human
GBM and ovarian cancer and observed a significantly positive
correlation between LIF and CCL2, CD163, and CD206 in both
tumor types (Supplementary Fig. 6). No correlation was
observed between LIF and CXCL9. In order to validate these
results at the protein level, we analysed a cohort of 20 GBM
patients and performed LIF, CXCL9, CCL2, CD163, and
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Fig. 1 LIF blockade decreases tumor growth and regulates immune cell infiltration. a Top-panel, distribution of LIF mRNA expression (log2 RSEM) across 28
distinct solid tumors (see Supplementary Data 1b) in boxplots (middle line depicts the median and the whiskers the interquartile range). Black line
represents the estimated cut-off between low expression/background noise. Bottom panel, correlation values (Pearson R2 values) between LIF expression
and the relative abundance of TAMs based on ssGSEA of the gene signature (see Supplementary Data 1a). Correlation values are only shown if the
correlation is significant (adjusted P-value < 0.1) (see Supplementary Data 1c). Cancer types are sorted according correlation value between LIF and TAMs
relative abundance. b Linear regression plots of LIF expression and relative abundance (ssGSEA rescaled from 0 to 1 for visualization purposes) of TAMs in
GBM, prostate adenocarcinoma (PRAD), thyroid carcinoma (THCA) and ovarian carcinoma (OV) cohorts. Shade represents the confidence intervals of the
regression estimate. c, i, l Tumor growth of GL261N (c), RCAS (i), and ID8 (l) models measured as total flux (p/s) or abdominal volume (mm3),
respectively. Scheme representing the experimental procedure is shown. Anti-LIF or isotype control (IgG) treatment started on the day of surgery (GL261N
and RCAS) or 14 days post-inoculation (dpi) (ID8). d, m Representative p-STAT3, Ki67, CC3, and CD8 IHC images and percentages of staining for GL261N
(d) and ID8 (m) tumors. e, n Representative images of GL261N (e) and ID8 (n) tumor-bearing mice treated with anti-LIF or IgG. f–g, j–k, o–p, Percentages
of CD11b+ F4/80+ CD163+ CD206+ MHCIIlow TAMs (f, o) or CD11b+ Ly6G− Ly6C− CD163+ CD206+ MHCIIlow (j) and CD8+ T cells (CD3+ CD8+) of
GL261N (g), RCAS (k), and ID8 (p) tumors analysed by flow cytometry. h, q, Overall survival of GL261N (h) and ID8 (q) models treated with anti-LIF or
IgG. Data are mean ± SEM. Statistical analyses by Mann–Whitney T-test and Log-rank test. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001
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CD206 IHC of the tumors. We noted a strong positive
correlation between LIF and CCL2, CD163 and CD206
(Fig. 2g, h). CXCL9 was expressed in isolated clusters of cells
and its levels showed an inverse correlation with LIF in human
GBM (Fig. 2g, h).
LIF induces the epigenetic silencing of CXCL9. We decided to
explore the molecular mechanisms involved in the regulation of
CXCL9 by LIF in macrophages. To this end, we studied the effect
of LIF on primary cultures of mouse bone marrow derived
macrophages (BMDMs). LIF regulated the expression of several
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M1-like and M2-like markers induced by IFNγ or IL4 in BMDMs
(Fig. 3a). CXCL9 expression was not detected except when
BMDMs were treated with IFNγ. Recombinant LIF repressed the
induction of CXCL9 by IFNγ both at the mRNA or protein levels
(Fig. 3b, c). A similar result was observed when BMDMs were
treated with LPS (Supplementary Fig. 7a). Importantly, CXCL9
was also regulated by IFNγ and LIF in patient-derived TAMs
(CD11b+ CD14+) obtained from fresh human GBM tumors
(Fig. 3d, Supplementary Fig. 7b, c). Thus, LIF acted as a repressor
of CXCL9 induction. CXCL9 has been described to undergo
epigenetic regulation18 and LIF is known to regulate the epige-
netic status of embryonic stem cells1,19. In line with this, we
found that treatment with LIF increased the levels of H3 lysine 27
trimethylated (H3K27me3), decreased the levels of acetylated H4
(H4ac), and increased EZH2 binding to the CXCL9 promoter
region, altogether showing that LIF was regulating CXCL9
expression through epigenetic silencing (Fig. 3e).
LIF regulates CD8+ T cell tumor infiltration. To confirm that
LIF regulates immune cell tumor infiltration through the
repression of CXCL9 in tumors from actual cancer patients, we
generated organotypic tissue cultures of GBM specimens freshly
obtained from patients. These organotypic models allow for the
short-term culture of tumor slices that maintain the tissue
architecture and stroma (including immune cells) of the patient’s
tumor20. We obtained organotypic tissue cultures from three
patient-derived tumors expressing high levels of LIF (Fig. 3f,
Supplementary Fig. 8). In all three cultures a large infiltration of
TAMs was present as detected by the Iba1 marker and most of
the TAMs expressed CCL2, CD163, and CD206. Interestingly, a
3-day treatment of the organotypic culture with a neutralizing
antibody against LIF promoted a decrease in CCL2, CD163, and
CD206 and an increase in CXCL9 expression (Fig. 3f, Supple-
mentary Fig. 8).
We then decided to test whether the regulation of LIF could
impact on the immune cell tumor infiltration. After anti-LIF
treatment, we incubated the organotypic slices from three patient-
derived tumors (expressing high levels of LIF) with peripheral
blood mononuclear cells (PBMCs) from the same patient (Fig. 4a).
Treatment with anti-LIF increased CXCL9 and decreased CCL2
expression (Fig. 4b), while inducing immune cell infiltration into
the Matrigel surrounding the tumor specimen (Fig. 4b). Notably,
CD8+ T cells were recruited to the tumor tissue upon LIF
blockade (Fig. 4b, c, Supplementary Fig. 9) and this effect was
dependent on CXCL9, since its neutralization prevented CD8+ T
cell infiltration (Fig. 4d).
We next decided to confirm this result in the context of an
in vivo model. We inoculated tumor fragments from four
patients, whose tumors expressed high LIF levels, in NSG mice
and treated these mice with the LIF neutralizing antibody for
5 days. Next, we inoculated each patient’s PBMCs in the mice and
analyzed the short-term tumor infiltration of T cells. Note that
this experimental model cannot be used for long experiments,
and hence survival analysis, due to graft-versus-host disease.
Interestingly, mice treated with anti-LIF showed an increase in
CD8+ T cell tumor infiltration and most of the infiltrating CD8+
T cells expressed the CXCL9 receptor, CXCR3 (Fig. 4e,
Supplementary Fig. 10a, b). We also isolated CD3+ T cells from
PBMCs and infected them with lentiviruses encoding luciferase.
Interestingly, most of the cells expressed CXCR3. We inoculated
these cells in mice bearing patient-derived tumors and were able
to monitor the anti-LIF-mediated CD3+ T cell tumor infiltration
by bioluminescence (Fig. 4f, Supplementary Fig. 10c, d)
LIF and PD1 blockade promotes tumor regression. So far, our
data indicated that the inhibition of LIF induced a change in the
phenotype of TAMs increasing the expression of CXCL9 and
leading to the recruitment of CD8+ T cells to the tumor. As
expected based on the literature21,22, we observed that a sub-
population of CD8+ T cells within the tumor in our mouse
models were PD1 positive (see Supplementary Fig. 3b, c). This
indicated that the blockade of PD1 in this context might increase
the anti-tumor response to anti-LIF agents. We decided to use
our immunocompetent mouse models bearing overt tumors with
anti-LIF and anti-PD1 antibodies and observed that the combi-
nation of the blockade of LIF and PD1 further decreased tumor
growth when compared to each individual treatment. Moreover
and importantly, the combined treatment with anti-LIF and anti-
PD1 increased overall survival and induced tumor regression
(Fig. 4g, h).
We collected the mice exhibiting complete tumor regression
and reinoculated 3 × 105 tumor cells. No tumor appeared in these
mice while tumors rapidly grew in naive mice inoculated in
parallel with the same number of cells (Fig. 4i). The result of this
rechallenge experiment indicated that the combined treatment
with anti-LIF and anti-PD1 generated immunological memory.
Discussion
CD8+ T tumor infiltration and TAMs determine among other
things the response to cancer immunotherapy17,23–27. We have
observed that LIF acts as an oncogenic factor through the reg-
ulation of the immune system. LIF establishes a cross-talk
between the innate and the adaptive immune response since LIF
neutralization regulates the expression of a chemokine program
in TAMs, including CXCL9, leading to an increase in CD8+ T cell
tumor infiltration (Fig. 4j). This indicates that LIF is responsible
for CD8+ T cell tumor exclusion and that it could be involved in
resistance to immune checkpoint blockade. Indeed, we explored
transcriptomic data of checkpoint inhibitor clinical trials28 and
observed that LIF, and the genes that we found regulated by LIF,
were associated to resistance to checkpoint inhibitor therapy
(Supplementary Fig. 11).
Fig. 2 LIF regulates CXCL9, CCL2, CD206, and CD163 in TAMs. a Differential expression analysis of isolated CD11b+ cells from anti-LIF treated ID8 mice
vs. control. Volcano plot representing the genes significantly (Q-value < 0.1) overexpressed (brown) and significantly underexpressed (turquoise).
Heatmap representing the expression values of the indicated genes, each column represents a sample and each row a gene. The last column represents the
log2 fold change (log2 FC) of gene expression. b mRNA expression for the indicated genes in isolated CD11b+ cells from anti-LIF treated or untreated ID8
and GL261N tumors. c Percentage and mean fluorescence intensity (MFI) of CCL2 and CXCL9 in TAMs (CD11b+ Ly6G− Ly6C−) from anti-LIF treated or
untreated GL261N tumors. d Representative IF images of Iba1 and the indicated markers stainings of GL261N tumors (see Supplementary Fig. 4). Scale bar,
20 μm. Bottom, percentage of double positive cells relative to the TAM marker positive cells. CXCL9 quantification is relative to the total number of cells.
e Tumor growth of GL261N in WT, CXCL9−/−, and CCL2−/− mice or mice treated with the indicated antibodies is shown as total flux (p/s). f Fold change
(FC) of tumor infiltrating CD8+ T cells in the indicated treatments. Data are mean ± SEM. g, h Representative IHC of the indicated markers from 20 GBM
tumors. The degree of staining was quantified using H-score method. Correlations between LIF and CCL2, CD206, CD163, and CXCL9 with the R-squared
coefficients (R2) were calculated (h). Statistical analyses by Mann–Whitney T-test. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-10369-9 ARTICLE
NATURE COMMUNICATIONS |         (2019) 10:2416 | https://doi.org/10.1038/s41467-019-10369-9 | www.nature.com/naturecommunications 5
2.5 × 104a
b
f
c d e
2 × 104
1 × 104 200
0.2 20 2
1.5
1
0.5
0
15
10
5
0
0.15
0.1
0.05
0
Promoter GAPDH
H3K27me3
M.m.
–988
CXCL9 promoter Control
LIF
Control
α-LIF
–458
EZH2 H4ac
CXCL9 GAPDH CXCL9 GAPDH CXCL9
150
100
50
0
15
10
5
0
60
40
20
0
8 × 103
6 × 103
4 × 103
2 × 103
0
20
15
10
5
0
20
15
10
5
0
1.5 × 104
1 × 104
5 × 103
0
60
40
20
0
40 800 15
10
5
0
600
400
200
0
30
20
10
0
CX
CL
9 
m
RN
A
CC
L2
 m
RN
A
CX
CL
9 
m
RN
A
CX
CL
9 
pg
/m
l
CX
CL
9 
pg
/m
l
R
el
at
ive
 e
n
ric
hm
en
t
AR
G
1 
m
RN
A
CD
20
6 
m
RN
A
IL
10
 m
RN
A
TN
Fα
 m
R
N
A
N
O
S2
 m
RN
A
CC
L5
 m
RN
A
2 × 104
1.5 × 104
1 × 104
5 × 103
0
LIF –
– – – –
–
– –
– ––
+ +
****
****
****
****
****
***
***
**
***
***
** **
**** ***
**
**** **** ***
***
********
*** *** ***
+
+
+ +
+IFNγ
IL4
LIF –
– – – –
–
– –
– ––
+ + +
–
– –
– –+
–
– –
–+
+ +
++ + – + – +
+
+ +
+IFNγ
LIF
IFNγ
Control
DA
PI
/Ib
a1
/L
IF
DA
PI
/Ib
a1
/C
XC
L9
DA
PI
/Ib
a1
/C
D2
06
DA
PI
/Ib
a1
/C
D1
63
DA
PI
/Ib
a1
/C
CL
2
Patient 1 Patient 2 Patient 3
Control Control
α-LIF α-LIF α-LIF
60
40
20CX
CL
9+
CD
20
6+
/Ib
a1
+
CD
16
3+
/Ib
a1
+
CC
L2
+
/Ib
a1
+
0
100
80
60
40
20
0
100
80
60
40
20
0
100
80
60
40
20
0
% of cells
***
***
***
**
LIF
IFNγ
–
– –
–+
+ +
+LIF
IFNγ
IL4
LIF –
– – – –
–
– –
– ––
+ + +
+
+ +
+IFNγ
IL4
LIF –
– – – –
–
– –
– ––
+ + +
+
+ +
+IFNγ
IL4
LIF –
– – – –
–
– –
– ––
+ + +
+
+ +
+IFNγ
IL4
LIF –
– – – –
–
– –
– ––
+ + +
+
+ +
+IFNγ
IL4
LIF –
– – – –
–
– –
– ––
+ + +
+
+ +
+IFNγ
IL4
LIF –
– – – –
–
– –
– ––
+ + +
+
+ +
+IFNγ
IL4
Fig. 3 LIF represses CXCL9 through epigenetic silencing. a, b qRT-PCR analysis of the indicated genes in BMDMs. BMDMs were pre-incubated with 20 ng/ml
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BMDMs pre-incubated with 20 ng/ml LIF and then stimulated with 0.1 ng/ml IFNγ for 24 h. d CXCL9 ELISA from human CD11b+sorted cells (77% CD11b+
CD14+, see Supplementary Fig. 7b, c) from human GBM cultured with 20 ng/ml LIF for 72 h and then with 0.1 ng/ml IFNγ for 24 h. e ChIP of Tri-methyl-
histone H3 (H3K27me3), EZH2 and acetyl-histone4 (H4ac) was performed in BMDMs treated with 20 ng/ml LIF for 72 h. Scheme shows the analysed
CXCL9 promoter region. Representative data are presented as mean ± SD. f Representative images of IF of the indicated markers in human GBM organotypic
slices (patients 1, 2, 3) incubated with 10 μg/ml anti-LIF for 3 days. Scale bar, 20 μm. (see Supplementary Fig. 8). Bottom, percentage of double positive cells
relative to Iba1+ cells and percentage of CXCL9+ cells relative to the total number of cells. Data are mean of all patients ± SEM. Statistical analyses by
Student’s t-test or Mann–Whitney T-test. *P < 0.05, **P < 0.01; ***P < 0.001; ****P < 0.0001
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-10369-9
6 NATURE COMMUNICATIONS |         (2019) 10:2416 | https://doi.org/10.1038/s41467-019-10369-9 | www.nature.com/naturecommunications
The immunosuppressive response to LIF is not only seen in
cancer. LIF has been shown to inhibit the immune response
in organ transplantation29, autoimmune diseases30 as well as in
embryo implantation2,6. As in many other cases, cancer hijacks a
normal developmental program for its own gain. LIF has been
designed through evolution to protect the embryo from the
immune system of the mother and prevent early differentiation of
ESCs. Tumors abduce this dual mechanism of action by secreting
aberrantly high levels of LIF. In this way, LIF protects tumors
from the host immune response and, as we and others have
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previously reported8,31, prevents differentiation of cancer-
initiating cells.
Our work reveals a promising therapeutic target in cancer. The
blockade of LIF in tumors expressing high levels of LIF promotes
effector T cell tumor infiltration transforming a T cell excluded
tumor into an inflamed tumor. This effect synergizes with
checkpoint inhibitors inducing tumor regression in very aggres-
sive tumors such as GBM. Therapies directed against LIF may
therefore have broad applications in the treatment of cancer.
Methods
Patients. Human GBM specimens were obtained from the Vall d’Hebron Uni-
versity Hospital and Clinic Hospital. The clinical protocol was approved by the Vall
d’Hebron Institutional Review Board and Clinic Hospital (CEIC), with informed
consent obtained from all subjects.
Human tumoroid and organotypic slice cultures. GBM tumoroids were gener-
ated as follows8. Briefly, tumor samples were processed within 30 min after surgical
resection. Minced pieces of human GBM samples were digested with 200 U/ml
collagenase I (Sigma) and 500 U/ml DNase I (Sigma) in PBS for 1 h at 37 °C with
constant vigorous agitation. The single-cell suspension was filtered through a 70
μm cell strainer (BD Falcon) and washed with PBS. Finally, cells were resuspended
and subsequently cultured in GBM medium that consisted of Neurobasal medium
supplemented with B27, penicillin/streptomycin (all from Life Technologies) and
growth factors (20 ng/ml EGF and 20 ng/ml FGF-2 (PeproTech)). GBM organo-
typic slice cultures were generated as follows. After resection, surgical specimens
were cut with a scalpel into rectangular blocks of 5–10 mm length and 1–2 mm
width and individually transferred into 0.4 µm membrane culture inserts (Milli-
pore) within 6-well plates. Before placing the inserts into 6-well plates, 1.2 ml of
Neurobasal medium (Life Technologies) supplemented with B27 (Life Technolo-
gies), penicillin/streptomycin (Life Technologies) and growth factors (20 ng/ml
EGF and 20 ng/ml FGF-2) (PeproTech) were placed into each well. The cultures
were kept at 37 °C with constant humidity, 95% air and 5% CO2. After one day,
slices were treated with 10 µg/ml of a rat anti-mouse/human LIF blocking antibody
(referred to as anti-LIF) (developed in house) or with its corresponding normal IgG
(10 µg/ml) for 3 days. For the blocking CXCL9 studies, a neutralizing mouse
monoclonal antibody against human CXCL9 (R&D Systems; MAB392) was added
to the culture at 1.5 µg/ml. In some occasions, 0.1 ng/ml of human rIFNγ (R&D
Systems) was added for 24 h. In parallel, peripheral blood mononuclear cells
(PBMCs) were obtained from the whole blood of the same patient by centrifuge
density separation using Lymphosep (Biowest). PBMCs were cryopreserved in
RPMI medium supplemented with 10% inactivated FBS and 10% DMSO until use.
For immune cell infiltration assays, control or anti-LIF slices were embedded
into growth factor deprived Matrigel (Corning) with subsequent addition of 1 × 106
PBMCs into 24-well plate in complete (10% inactivated FBS) RPMI medium. In
addition, supernatants were collected and organotypic slices were recovered from
Matrigel and further processed for IF and flow cytometry. In some conditions,
PBMCs were resuspended with PBS at a concentration of 1 × 106 cells/ml and
incubated for 20 min with 5 µM Cell Trace CFSE (Invitrogen). After the incuba-
tion, cells were washed with RPMI and added to the sections embedded into
Matrigel. After 24 h, fluorescent PBMCs invasion into Matrigel was evaluated
under microscope by counting migrating cells in five different areas per each
condition.
Animals and in vivo experiments. All animal experiments were approved by and
performed according to the guidelines of the Institutional Animal Care Committee
of the Vall d’Hebron Research Institute in agreement with the European Union and
national directives. Female C57BL/6 and NOD/SCID were purchased from Janvier,
RAG−/−, CCL2−/− and CXCL9−/− from Jackson Laboratories and NOD scid
gamma (NSG) from Charles River. For brain tumor models, 3 × 105 GL261N,
GL261 or RCAS cells, all of them with luciferase expression, were stereotactically
inoculated into the corpus striatum of the right brain hemisphere (1 mm anterior
and 1.8 mm lateral to the lambda; 2.5 mm intraparenchymal) of 8-week-old
C57BL/6 mice. For ovary tumor model, 5 × 106 ID8 ovarian cancer cells were
intraperitoneally injected into 8-week-old C57BL/6 mice. A dose of 300 µg (ID8) or
600 µg (GL261N, GL261 and RCAS) of anti-LIF or a control IgG was administered
intraperitoneally twice a week. Additionally, a dose of 200 µg of rat anti-mouse
PD1 blocking antibody (anti-PD1, BioXCell; BE0146), anti-mouse/human/rat
CCL2 antibody (MCP-1, BioXcell; BE0185) or 3 µg of anti-mouse CXCL9 antibody
(R&D; AF-492-NA) was administered intraperitoneally twice a week. Tumor
progression was monitored by body weight and by abdominal girth (ID8), or
bioluminescence measurements using the Xenogen IVIS® Spectrum (GL261N,
GL261, and RCAS). Mice were euthanized when they exhibited clinical signs of
disease or distress (i.e., cachexia, anorexia, or increased respiratory rates) or when
tumors began to interfere with normal body functions.
For brain tumor transplantation, GL261N tumors were isolated from tumor-
bearing mice, embedded in pieces into Matrigel and subcutaneously implanted in
new control or anti-LIF treated mice.
For regression study, 3 × 105 GL261N cells were inoculated in 6 tumor bearing-
mice with complete regression after anti-LIF, anti-PD1 combination treatment.
Ten naive mice were inoculated 3 × 105 GL261N cells in parallel.
Primary cell cultures and cell lines. BMDMs were obtained from 6 to 10-week-
old C57BL/6 mice32. Briefly, bone marrow precursors were cultured in DMEM
(Life Technologies), supplemented with 20% heat inactivated FBS and 30% L-cell
conditioned medium (cm) as a source of macrophage-colony stimulating factor.
Differentiated macrophages were obtained after 6 days culture. L-cell cm was
obtained from L929 cells grown in DMEM supplemented with 10% heat-
inactivated FBS (Life Technologies). Human macrophages were isolated from
human GBM specimens. Briefly, tumor tissue was enzymatically digested with
Tumor Dissociation kit and CD11b+ cells were isolated using CD11b magnetic
beads and the MultiMACS Cell24 separator Plus (all from Miltenyi Biotec). CD11b
+ cells obtained were cultured in RPMI medium supplemented with 10% heat-
inactivated FBS (Life Technologies). Recombinant LIF, IFNγ, LPS, and IL4 were
purchased from Millipore, R&D Systems, Sigma and Creative BioMart,
respectively.
GL261N were derived from GL261 cells that were obtained from Charles River
and cultured in RPMI (Life Technologies). ID8 was a generous gift from Dr.
George Coukos, Ludwing Institute for Cancer Research, Lausanne, and cultured in
DMEM. The media for both cell lines were supplemented with 10% FBS and
penicillin/streptomycin (Life Technologies). RCAS GFAP-tva PDGFA, shp53,
shNF1 (RCAS) cells13 were cultured in Neurocult basal medium supplemented
with Neurocult proliferation supplement, heparin, FGF, and EGF (all from
StemCell Technologies).
GBM patient-derived in vivo models. Surgical human GBM specimens were cut
with a scalpel into rectangular blocks of 5–10 mm length and 1–2 mm width and
transferred into a tube containing 100 µl of Matrigel (Corning) supplemented with
5 ng/ml of rIFNγ (R&D Systems). Each specimen was introduced subcutaneously
into one or two flanks of 4 to 5-weeks-old NSG mice. Half of the mice received
anti-LIF (600 µg) treatment every three days starting at the day of the implantation
of the samples. Minimum of three specimens per condition were implanted. After
5 days, 1 × 107 PBMCs obtained from the same patient, and previously stimulated
with 150 U/ml of rIL2 (R&D Systems) for 24 h, were intravenously inoculated into
the mice in exception of one (control without PBMCs). Forty-eight hours post-
inoculation, engrafted tumors were collected and processed to determine CD8+
Fig. 4 LIF blockade induces CD8+ T cell tumor infiltration and promotes tumor regression when combined with anti-PD1. a Schematic representation of
GBM patient-derived xenografts and human organotypic models. b Organotypic specimens were treated with anti-LIF for 72 h and then cultured with
PBMCs for 24 h. CXCL9 and CCL2 mRNA expression levels are shown. Representative images (patient 4, 5, 6) of CFSE-stained PBMCs into Matrigel
containing GBM specimens and IF of the indicated factors in organotypic tissues are displayed. Bars represent quantification of five different fields of each
condition. Data are presented as mean ± SD. Scale bar, 20 μm. c, d FC of CD8+ T infiltrating cells detected by flow cytometry in organotypic tissues treated
with anti-LIF (c, d) and/or anti-CXCL9 (1.5 μg/ml) (d) for 72 h and then cultured with PBMCs for 48 h (patient 4, 5, 6). e CD8+ T infiltrating cells into
subcutaneously engrafted GBM specimens in NSG mice. Bar graph represents the ratio of CD8+ T cells detected by flow cytometry in the tissue vs. CD8+
T cells detected in the blood of the same animal. Four patients (7, 8, 9, 10) with their corresponding PBMCs were evaluated and are represented with
different colors. f Representative images of treated or untreated patient-derived xenografts (PDX) bearing mice 48 h after luciferase CD3+ T cells
inoculation. T cells infiltration is measured as total flux (p/s) within the tumor. Data are mean ± SEM. g Scheme represents the experimental procedure of
GL261N mice treated with anti-LIF, anti-PD1 or the combination. Overall survival determined by Kaplan-Meier curves is shown. h Tumor growth of the
treated GL261N model represented as a fold change of tumor size between 13 and 6 dpi. Representative images are shown. i Scheme representing the
experimental procedure for regression study. Images of mice and tumor size measured by total flux (p/s) at 13 dpi are shown. j Schematic representation
shows the effect of LIF in CD8+ T cell tumor infiltration. Statistical analyses by Mann–Whitney T-test or Log-rank test. *P < 0.05; **P < 0.01; ***P < 0.001
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T cells infiltration by flow cytometry. Total blood of the mice was also processed
using Ficoll-Paque Premium (Ge Healthcare) in order to obtain the PBMCs.
For immune cell infiltration assay, 1 × 107 of luciferase expressing CD3+ T cells
were intravenously introduced into control or anti-LIF (600 µg) treated GBM
patient-derived models. After 48 h CD3+ T cells recruitment into the tumor was
monitored by bioluminescence measurements using the Xenogen IVIS® Spectrum.
Tumor digestion, flow cytometry, and cell isolation. Mice were euthanized and
tumors were isolated. GL261N and RCAS tumors were enzymatically digested with
Brain Tumor Dissociation kit and myelin was removed with Myelin Removal Beads
II (all from Miltenyi Biotec). ID8 tumors were processed with Mouse Tumor
Dissociation kit (Miltenyi Biotec) and ascitic liquids were collected. Human GBM
specimens of the organotypic model and the patient-derived xenografts were
enzymatically digested with Human Tumor Dissociation kit (Miltenyi Biotec).
From GL261N cell suspension, CD11b+ cells isolation was performed using
anti-Ly6C-APC and anti-APC microbeads and anti Ly6G microbeads to deplete
Ly6G+ and Ly6C+ populations and then with CD11b magnetic beads. CD45+ cells
isolation was performed with anti-mouse CD45 magnetic beads. From ID8 cell
suspension, CD11b+ cells were isolated using anti-CD11b magnetic beads. Finally,
from organotypic slices, CD45+ cells isolation was performed using anti-human
CD45 magnetic beads. All the isolation procedures were performed using the
MultiMACS Cell24 separator Plus following manufacturer instructions and
magnetic beads were purchased from Miltenyi Biotec.
The murine antibodies against CD3 (17-0032-82; 1:40), CD4 (11-0042-81;
1:250), CD335 (25-3351-82; 1:20), CD163 (12-1631-82; 1:40, MHC class II (47-
5321-82; 1:80), CXCR3 (12-1831-82; 1:40) from eBioscience, CD45 (BD-550994;
1:200), CD8 (BD-557654; 1:40), F4/80 (BD-565410; 1:25), CD11b (BD-553310;
1:100), CD11c (BD-550261; 1:100), CD206 (BD-565250; 1:30), CD49d (BD-
740012; 1:30) from BD Bioscience, LIFR (Novus FAB5990N; 1:20) from Novus
Biologicals, Ly6G (127622; 1:200), Ly6C (128018; 1:150), CCR2 (150604; 1:50) and
PD1 (135208; 1:80) from Biolegend were used for flow cytometry. Intracellular
staining of FoxP3 (12-5773-82; 1:40), Granzyme A (GZMA) (48-5831-82; 1:80),
CXCL9 (12-3009-80; 1:40) from eBioscience and CCL2 (505910; 1:100; Biolegend)
were performed using a specific staining set (eBioscience). For flow human studies,
antibodies against CD11b (333142; 1:100), CD14 (555397; 1:100) from BD
Bioscience, CD45 (304032; 1:100), CD3 (344816; 1:100), CXCR3 (353708; 1:100)
from Biolegend and CD8 (560179; 1:75; BD Pharmigen) were used. In some
occasions samples were previously incubated with LIVE/DEAD fixable yellow dead
stain kit (L34959; 1:2000;Thermo Fisher Scientific) to determine viability. As a
positive control of human GBM organotypic and patient derived xenografts,
1 × 106 PBMCs (named as “spike PBMCs”) was added into the control samples in
order to establish the leukocyte populations.
Samples were acquired on a BD LSRFortessa™ cell analyser or Navios (Beckman
Coulter) and data were analysed with Flow Jo software.
Lentiviral infection. 293T cells were transfected using lipofectamine 2000 (Invi-
trogen) transfection method with pMD2.G enveloping plasmid, psPAX.2 packa-
ging plasmid, and either pLenti CMV Luciferase (v-168-1) (Addgene), pLKO.1 or
pLKO.1-shLIF murine (Sigma). After 16 h, medium was replaced by fresh medium
and lentivirus was harvested for an additional 24 h. For cell lines infection, medium
containing recombinant lentivirus was added to cells with polybrene (Sigma) at a
concentration of 8 µg/ml. Following 16 h of incubation, cells were washed and
incubated in fresh medium previous to selection.
CD3+ T cells were negatively isolated from PBMCs using Dynabeads
Untouched Human T cell Kit (Thermo Fisher). Isolated CD3+ T cells were infected
with lentivirus vectors33. Briefly, a 24 well plate was pre-coated for 1 h at 37 °C with
1 µg/ml of anti-CD3 (clone OKT3, Thermo Fisher Scientific) and 5 µg/ml of CH-
296 (Retronectin recombinant fibronectin fragment, Takara). CD3+ T cells were
resuspended at concentration of 0.7 × 106 cells/ml with RPMI supplemented with
10% heat-inactivated FBS and 600 IU/ml of rIL2 (R&D systems). 0.4 ml of cell
suspension was mixed with 1 ml of luciferase lentiviral vector (supplemented with
600 IU/ml of rIL2 and 8 µg/ml of polybrene) and seeded into anti-CD3/CH-296
coated 24-well plate. Plate was centrifuged at 1000×g for 30 min at 32 °C. The day
after, medium was replaced by fresh RPMI supplemented with 10% heat-
inactivated FBS and 600 IU/ml of rIL2. After 4 days cells were subcultured 1:2 into
new anti-CD3/CH-296 pre-coated 24-well plate until used. At same time point,
luciferase was determined by the luciferase assay system (Promega).
CRISPR/LIF cell line generation. Cells were transfected with the commercial
mouse LIF CRISPR/Cas9 KO plasmid (Santa Cruz Biotechnology) following
manufacturer’s specifications. Green Fluorescent Protein (GFP) was used as a
selective label. After 3 days, transfected cells were selected by sorting. CRISPR/LIF-
KO positive cells were checked by qRT-PCR and ELISA.
ELISA. For the quantitative determination of CXCL9 and CCL2 protein levels
secreted to the media, and IL10 and IL12 protein levels from tumor tissue, we used
the Mouse or Human Duo-Set ELISA kit (R&D systems) following manufacturer’s
specifications.
Quantitative real-time PCR. Cells were lysed for mRNA extraction (RNeasy Mini
or Micro Kit, Qiagen), retrotranscription (iScript Reverse Supermix from BioRad
for mRNA), and qRT-PCR was performed using Taqman probes from Applied
Biosystems, according to manufacturer’s recommendations. For paraffin-
embedded sections, RNA was obtained by using High Pure FFPET RNA isolation
kit (Roche) and following manufacturer instructions. Reactions were carried out in
a CFX384 Touch™ Real-Time PCR Detection System (Bio-Rad) and results were
expressed as fold change calculated by the Ct method relative to the control sample.
Murine or human ACTB or GAPDH were used as internal normalization controls.
Immunohistochemical and immunofluorescence staining. Immunohistochem-
ical (IHC) staining was performed as follows. Slides were deparaffinized and
hydrated. Antigen retrieval was performed using pH 6 or pH 9 Citrate Antigen
Retrieval Solution (DAKO), 10 min 10% peroxidase (H2O2) and blocking solution
(2% BSA) for 1 h at room temperature. As a detection system, EnVision FLEX+
(DAKO) was used according to the manufacturer’s instructions, followed by
counterstaining with hematoxilin, dehydration and mounting (DPX). The quan-
tification of LIF, CCL2, CD163, CD206, and CXCL9 staining in GBM tumors from
patients was expressed as H-score (3× percentage of strong staining+ 2× per-
centage of moderate staining+ percentage of weak staining), giving a range of
0–300. Quantification of p-STAT3, Ki67, CC3, and CD8 was performed with
ImageJ, counting the total number of cells of three different fields per mouse, five
mice/group, and calculating the percentage of positive cells. Data in graphs are
presented as mean ± SEM.
IHC antibodies: human LIF (Atlas; HPA018844; 1:200), murine LIF (Atlas;
HPA018844; 1:300), murine p-STAT3 (Cell Signaling; 9131; 1:50), murine Ki67
(AbCam; ab15580; 1:200), murine Cleaved-Caspase3 (CC3) (Cell Signaling; 9661;
1:500), murine CD8 (Bioss; bs-0648R; 1:200), human/murine CCL2 (Novus
Biologicals;NBP2-22115; 1:200), human CXCL9 (Thermo Fischer Scientific;
701117; 1:100), human CD206 (Abcam; ab64693; 1:4000) and human CD163
(Leica Novacastra; NCL-L-CD163; 1:200).
Immunofluorescence (IF) staining was performed as follows. Nuclei were
counterstained with DAPI and images were captured using a laser scanning
confocal NIKON Eclipse Ti microscope. Quantification of immunofluorescence
were performed with ImageJ, counting all or up to 100 cells positive for CD11b,
Iba1, or CD3 of 2–3 different fields of each mouse, 3–5 mice/group, and calculating
the percentage of those cells positive for CCL2, CD206, and CD163 inside the Iba1
positive population. For CXCL9, it was calculated the percentage of cells
surrounded by the signal of this cytokine inside the total population of cells. For
organotypic slices, 3–4 fields of each patient (n= 3) were quantified. For
organotypic tissue immunofluorescence, five different Z-stack images per condition
were processed with Fiji-Image J software. For CD8+ T cells, percentage of CD8+
T cells was calculated among the total population. Data in graphs are represented
as mean ± SEM.
IF antibodies: human/murine CCL2 (Novus Biologicals; NBP-22115; 1:200),
human/murine Iba1 (Wako; 019-19741; 1:1000 and Abcam; ab5076; 1:50), human/
murine CD206 (Abcam; ab64693; 1:500), murine CD163 (Abcam; ab199402;
1:200), CXCL9 (murine R&D; AF-492-NA; 1:200; human Thermo Fischer
Scientific; 701117; 1:200), human CD8 (DAKO; M7103; 1:200), human LIF (Atlas;
HPA018844; 1:200) and human CD163 (Leica Novocastra; NCL-L-CD163; 1:200).
Microarray expression analysis. RNA was assayed on the Affymetrix microarray
platform with the Mouse Gene 2.1 ST. Next, it was normalized based on a Robust-
Microarray Average (RMA)34 (by Progenika). We identified the genes differentially
expressed in anti-LIF treated mice through a Bayesian linear regression considering
paired samples, using limma Bioconductor package35.
Chromatin immunoprecipitation assays. Immunoprecipitation of chromatin was
performed according to the Upstate (Millipore) standard protocol. Briefly, 1.2 × 107
BMDMs were fixed using 1% formaldehyde for 10 min at 37 °C, harvested, and
sonicated to generate chromatin fragments of 200–500 bp. Then 20 µg of sheared
chromatin was immunoprecipitated overnight with 2 µg of anti-Tri-Methyl-
Histone H3 (Lys27) (Cell Signaling; 97335), anti-acetyl-H4 (Millipore; 06–866) or
anti-EZH2 (Millipore; CS203195) antibody. Immunocomplexes were recovered
using 20 µl of protein G magnetic beads, washed, and eluted. Cross-linking was
reversed at 65 °C 4 h and immunoprecipitated DNA was recovered using the PCR
purification kit from Qiagen. Genomic regions of interest were identified by real-
time quantitative PCR (qPCR) using SYBR Green Master Mix (Invitrogen). Each
value was corrected by the corresponding input chromatin sample. CXCL9 pro-
moter was amplified using “CCCCGTTGCAATACTTTCAT” (forward) and
“CCCCGTTGCAATACTTTCAT” (reverse) primers (EZH2, acetyl-H4) or
“TGCTGTTGAATGCCACTTTC” (forward) and “TCCCTGCTACCTTTTC-
CAGA” (reverse) primers (H3me3). Mouse GAPDH promoter (Diagenode) was
amplified as a control.
TCGA data sets analysis. We downloaded RNA-seq data from The Cancer
Genome Atlas (TCGA) for 9,403 patients suffering from 28 distinct solid tumors
(see details on the tumor cohorts considered in Supplementary Data 1b) from
Firebrowse server (http://firebrowse.org, version 2016_01_28). The RNA-seq
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normalized data (RSEM) was log2 transformed for all downstream analyses. Next,
we obtained the gene signatures of TAMs from 37 (see Supplementary Data 1a).
Based on previous work36–38, we inferred the relative abundance of the immune
populations through a single sample gene set enrichment (ssGSEA)39 across all
patients. Thereafter we computed the correlation between LIF expression and the
ssGSEA scores of the four immune populations and the correlation between LIF
and a set of genes of interest (see Statistical tests).
Transcriptome analysis of metastatic urothelial carcinoma anti-PD1 treated
patients analysis. We downloaded RNA-seq from the phase 2 clinical trial
(IMvigor210) which investigates the clinical activity of PD-L1 blockade with ate-
zolizumab in metastatic urothelial carcinoma28 We downloaded RNA-seq data
(FASTQ files) and clinical annotations from the European Genome-Pheno Archive
(EGAS00001002556). We normalized RNA-seq counts into Transcripts per million
(TPM) for Homo Sapiens GRCh38 using Kallisto40. Two groups of patients, as
previously defined by the authors, were considered for downstream analyses based
on their clinical response to atezolizumab: non-responders (patients with Pro-
gressive Disease and Sustained Disease after treatment) and responders (patients
with Partial and Complete response after treatment). To compare the expression
levels of LIF between both groups TPMs were log2 transformed. Next, we per-
formed an enrichment analysis of the anti-LIF down-regulated genes in anti-PD1
non-responder patients. We considered as anti-LIF down-regulated genes those
genes with a log fold change (FC) <−1.5 in anti-LIF treated ID8 mice (see
Microarray expression analysis above). Then, we performed a pre-ranked Gene Set
Enrichment Analysis41, using gseapy Python3 package, on the genes differentially
expressed between non-responder and responder patients (we considered the log
FC as rank). Ranks were computed using rankdata Python3 SciPy package16.
Statistical analysis. Data were analysed using GraphPad Prism 5.0 software. To
compare two different groups we calculated P-value (P) using Student’s T-test
(paired or unpaired) for parametric variables and Mann–Whitney test for non-
parametric variables. Survival curves comparison was performed using Log-rank
(Mantel-Cox) test. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001. TCGA data
was analysed with Python3 SciPy library16, the correlation coefficient (R2) was
obtained using a Pearson’s correlation. P-values were adjusted for multiple testing
correction based on a Benjamini-Hochberg False Discovery Rate.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
The microarray data of the mice ovary tumor model has been deposited in the Gene
Expression Omnibus (GEO)/NCBI public database (accession no. GSE79852).
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